A Urinalysis is a laboratory test that enables clinicians to detect problems that can be observed through urine examination. Many illnesses and disorders, such as diabetes and kidney diseases, affect the body, and hamper the removal of waste and toxins. Growth of this market is primarily driven by the rising global prevalence of kidney diseases and urinary tract infections, the growing geriatric population, the introduction of technologically advanced Diagnostics, and the increasing adoption of point-of-care devices for urinalysis. However, the presence of ambiguous regulatory frameworks is expected to hinder the growth of this market.

The urinalysis market is expected to grow at a CAGR of 4.5% from 2020 to 2027 to reach $2.19 billion by 2027.

Here are the top 10 companies operating In  Urinalysis Market

F. Hoffmann-La Roche AG (Germany)

F. Hoffmann-La Roche AG is engaged in developing medicines for improving global healthcare standards with quality, safety, and efficacy. The company operates through two divisions: Pharmaceuticals and Diagnostics. The Diagnostics division consists of the following four Business areas: Centralised and Point-of-Care Solutions, Molecular Diagnostics, Diabetes Care, and Tissue Diagnostics. These business areas focus on healthcare applications, targeting physicians, hospitals and clinics, or consumers. The company provides urinalysis products under the Centralised and Point-of-Care Solutions segment of Roche’s Diagnostics business segment.

The company has a strong geographic presence across all regions. However, the company’s Diagnostics division has a strong geographic presence in Europe and the Middle East & Africa, followed by Asia-Pacific and North America. The major subsidiaries of the company operating in the urinalysis market include Roche sro (Czech Republic), Roche Diagnostics Australia Pty. Limited (Australia), Roche Diagnostics GmbH (Austria), Roche Diagnostics (Shanghai) Ltd. (China), Roche Diagnostics France SAS (France), and Roche Diagnostics Deutschland GmbH (Germany).

Sysmex Corporation (Japan)

Sysmex Corporation Sysmex Corporation develops, manufactures, sells, and exports/imports diagnostic instruments, reagents, and related software. Products are offered through two business segments: IVD Business and Life Sciences Business. The IVD Business segment is further sub-segmented into hematology, hemostasis, urinalysis, immunochemistry, clinical chemistry, FCM (flow cytometry), and others. The company offers urinalysis products through its IVD Business segment. The company serves customers, such as public hospitals, private hospitals, universities, research institutes, and other medical institutions.

The company provides products, services, and support to customers in more than 190 countries worldwide. It has its R&D sites at 24 locations across seven countries, instrument production bases in 6 locations, and reagent production bases in 13 locations, out of which, 7 locations have production bases for hematology and urinalysis reagents.

Cardinal Health, Inc. (U.S.)

Cardinal Health, Inc. Cardinal Health, Inc. is a provider of integrated healthcare services and products. The company conducts its business through two major business segments: Pharmaceutical and Medical. It offers integrated healthcare services and customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices.

The Pharmaceutical segment distributes branded and generic pharmaceuticals, specialty pharmaceutical products, and OTC healthcare and consumer products. The Medical Segment manufactures and distributes medical, surgical, and laboratory products in the U.S., Canada, Europe, Asia, and other markets. This segment also distributes medical products to patients’ homes in the U.S. through the Cardinal Health at-Home Solutions division. The company offers urinalysis products through its Medical Segment.

Outside the U.S., manufacturing facilities of the medical business segment are present in Canada, Costa Rica, the Dominican Republic, Germany, Ireland, Japan, Malaysia, Malta, Mexico, and Thailand.

Beckman Coulter, Inc. (U.S.)

Founded in 1935 and headquartered in Brea, California, U.S., Beckman Coulter, Inc. operates majorly in the clinical diagnostics industry. The company offers clinical diagnostic products and solutions, automation systems, and clinical information management tools to enhance the diagnostic laboratories’ role in improving patient diagnosis and treatment.

In 2011, Danaher Corporation acquired Beckman Coulter. All its operations are conducted under the Life Sciences and Diagnostics business segments of Danaher Corporation. Danaher Corporation operates through the Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions segments. The company offers urinalysis products through its Clinical Lab Diagnostics sub-segment of the Diagnostics business segment. The Diagnostics business products are generally marketed under the APERIO, BECKMAN COULTER, CEPHEID, HEMOCUE, IRIS, LEICA BIOSYSTEMS, MAMMATOME, RADIOMETER, and SURGIPATH brand names.

The company has manufacturing facilities for diagnostics products in North America, Europe, Asia, and Australia. Also, the Diagnostics business sales are primarily achieved through direct sales personnel and, to a lesser extent, through independent distributors. The major subsidiaries of the company operating in the urinalysis business segment include Beckman Coulter Biomedical GmbH (Germany), Beckman Coulter Canada LP (Canada), Beckman Coulter France S.A.S (France), Beckman Coulter Srl (Italy), Beckman Coulter Saudi Arabia Co. Ltd. (Saudi Arabia), and Beckman Coulter do Brasil Ltda. (Brazil).

Bio-Rad Laboratories, Inc. (U.S.)

Bio-Rad is engaged in developing and producing specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company’s products and solutions are based on technologies that separate, purify, identify, analyze, and amplify biological materials such as cells, bacteria, antibodies, proteins, and nucleic acids. The company operates through two business segments: Life Science and Clinical Diagnostics. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories. This business segment provides automated test systems, informatics systems, test kits, and specialized quality controls, including urinalysis products for the healthcare market. The company’s key customers in the urinalysis market include hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories.

The company has a direct presence in the U.S., France, Switzerland, Germany, Belgium, and Singapore through its manufacturing, research, and distribution facilities. The company also has direct distribution channels in over 35 countries through subsidiaries, distributors, and supply agents.

Meticulous Research in its latest publication on Global Urinalysis Market has predicted the growth of 4.5% during the forecast year 2020–2027

ARKRAY, Inc. (Japan)

Established in 1960 and headquartered in Kyoto, Japan, ARKRAY, Inc. manufactures diabetes care products and clinical chemistry equipment that are simple, convenient, and easytouse. These products include blood glucose meters, test strips, safety lancets, genetic testing, insulin safety syringes, and urine chemistry. These products are adopted by large to mid-sized and small hospitals, research institutes, and individual patients. The company has 22 main offices in 13 countries.

ACON Laboratories, Inc. (U.S.)

Founded in 1996 and headquartered in California, U.S., ACON Laboratories, Inc. manufactures diagnostic and medical products. The product lines include diabetes care, clinical chemistry (including urinalysis and point-of-care tests), veterinary diagnostics, and immunoassays. The products are marketed under the OptiLance, CentriVet, HealthyMe, Mission, OnCall, and Foresight brand names. These products are utilized by hospitals, clinical laboratories, physician offices, blood banks, pharmacies, veterinary clinics, and other channels across 130 countries. The company has a presence across the Americas, Asia, Europe, Africa, and Oceania.

Siemens Healthineers AG (Germany)

Siemens Healthineers AG is engaged in diagnostics and therapeutic imaging, laboratory diagnostics and molecular medicine, digital health, and enterprise. It was originally founded in 1847 and was known as Siemens Healthcare GmbH. In May 2016, Siemens Healthcare GmbH got rebranded as Siemens Healthineers. The company operates through three business segments, namely Imaging, Diagnostics, and Advanced Therapies. The company offers urinalysis products through its Diagnostics business segment.

With its subsidiaries and a strong distribution network, the company has its presence across Europe, the Commonwealth of Independent States (C.I.S.), Africa, the Middle East, the Americas, Asia, and Australia. Its major manufacturing and engineering sites are located in the U.S., Germany, Spain, the U.K., India, China, South Korea, and Brazil. The main production sites are in the U.S., China, and Germany.

Urit Medical Electronic Group Co., Ltd. (China)

Established in 1984 and headquartered in Guangxi, China, URIT Medical Electronic Group Co., Ltd., is a manufacturer of in-vitro diagnostic devices (IVD) and also provides a complete range of products& solutions for urinalysis, hematology, biochemistry, POC, electrolyte, coagulation, ELISA, and veterinary diagnostics. The company has more than 500partners and distributors and more than 20 local offices globally, while more than 100 branch offices and more than 3000 distributors are presentin the domestic market. The company has a geographic presence in over 180countries across North America, South America, Asia, Europe, Africa, the Commonwealth of Independent States (CIS), and the Middle East.

77 Elektronika Kft. (Hungary)

Established in 1986 and headquartered in Budapest, Hungary, 77 Elektronika is a developer, manufacturer, and supplier of in-vitro diagnostic devices (IVD). The company’s product portfolio includes urine analyzers, blood glucose meters, and consumables. The company supplies its products worldwide under its brand name, as well as OEM and ODM products for leading multinational companies in the field of medical diagnostics. The products are distributed in nearly 100 countries by local distributors. The company has its sales divisions present in Europe, Africa, Asia, Latin America, Australia, and Oceania.

Amidst this crisis, Meticulous Research® is continuously assessing the impact of the COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on industry here with Sample PDF

Authoritative Research on the Urinalysis Market – Global Opportunity Analysis and Industry Forecast (2020-2027)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

• Recent financial performance
• Key products
• Significant company strategies
• Partnerships and acquisitions
• Impact of Covid 19 on Urinalysis Market

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

Please download report pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=5089